Merck’s decision to pause Gardasil shipments to China due to low demand is expected to impact the company’s 2025 revenue projections. Despite this setback, Merck reported a robust profit increase in the fourth quarter, largely driven by Keytruda sales. Consequently, Merck’s shares dropped nearly 8% in premarket trading.
About the Author
